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ABSTRACT 
Current evidence indicates that excess brain cholesterol regulates amyloid-β (Aβ) 
deposition, which in turn can regulate cholesterol homeostasis. Moreover, Aβ 
neurotoxicity is potentiated, in part, by mitochondrial glutathione (mGSH) depletion. To 
better understand the relationship between alterations in cholesterol homeostasis and 
Alzheimer’s disease (AD), we generated a triple transgenic mice featuring sterol 
regulatory element-binding protein-2 (SREBP-2) overexpression in combination with 
APPswe/PS1∆E9 mutations (APP/PS1) to examine key biochemical and functional 
characteristics of AD. Unlike APP/PS1 mice, APP/PS1/SREBP-2 mice exhibited early 
mitochondrial cholesterol loading and mGSH depletion. Moreover, β-secretase 
activation and Aβ accumulation, correlating with oxidative damage and 
neuroinflammation, were accelerated in APP/PS1/SREBP-2 mice compared to APP/PS1 
mice. Triple transgenic mice displayed increased synaptotoxicity reflected by loss of 
synaptophysin and neuronal death, resulting in early object-recognition memory 
impairment associated with deficits in spatial memory. Interestingly, tau pathology was 
present in APP/PS1/SREBP-2 mice, manifested by increased tau hyperphosphorylation 
and cleavage, activation of tau kinases and neurofibrillary tangle formation without 
expression of mutated tau. Importantly, in vivo treatment with the cell permeable GSH 
ethyl ester, which restored mGSH levels in APP/PS1/SREBP-2 mice, partially 
prevented the activation of tau kinases, reduced abnormal tau aggregation and Aβ 
deposition, resulting in attenuated synaptic degeneration. Taken together, these results 
show that cholesterol-mediated mGSH depletion is a key event in AD progression, 
accelerating the onset of key neuropathological hallmarks of the disease. Thus, 
therapeutic approaches to recover mGSH may represent a relevant strategy in the 
treatment of AD.  
3 
 
  
4 
 
INTRODUCTION 
Cholesterol homeostasis is impaired in Alzheimer’s disease (AD) brain. Accumulation 
of sterols has been described in senile plaques and in affected brain areas from AD 
patients and mouse models (1-5), with reported region-specific loss of synapses related 
to changes in cholesterol levels (6). Although several studies examining the effect of 
different lipid lowering compounds in AD have produced mixed outcomes, the 
epidemiological data linking high cholesterol levels with increased amyloid-β (Aβ) 
production and prevalence of AD is supported by a growing number of in vivo and in 
vitro studies (7). Accordingly, cholesterol enrichment in lipid rafts has been postulated 
to up-regulate the activity of Aβ-synthesizing enzymes (8-10). Once generated, 
cholesterol levels can also influence Aβ aggregation state (11) and rate of degradation 
(12). In turn, Aβ has been described to modulate cholesterol homeostasis (1, 13, 14), 
establishing a self-sustained cycle between cholesterol accumulation and Aβ generation. 
In line with this vicious cycle, AD transgenic mice with acyl-
CoA:cholesterolacyltransferases deletion, exhibited reduced sterol synthesis rate and 
improved amyloid pathology (15). Moreover, subcutaneous administration of β-
cyclodextrin in Tg19959 mice significantly diminished Aβ deposition, tau 
phosphorylation and improved memory deficits (16), reinforcing the connection 
between altered cholesterol and AD pathology. Additionally, our previous studies have 
unraveled a new role of cholesterol in Aβ cytotoxicity, whereby mitochondrial 
cholesterol loading sensitized to Aβ neurotoxicity via mitochondrial glutathione 
(mGSH) depletion (5, 17). 
Although it is widely accepted that Aβ is an initial and important part in the 
pathogenesis of AD, additional factors such as abnormal tau phosphorylation associated 
with neurofibrillary tangle (NFT) formation are required for AD to progress from a 
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presymptomatic state to the appearance of dementia symptoms (18).  Interestingly, 
several lines of experimental evidence have shown that Aβ potentiates tau pathology, 
therefore positioning tau abnormalities downstream of Aβ in AD (19-21). It has been 
also suggested that hyperphosphorylation of tau may be attributable to mitochondrial 
oxidative stress (22). Furthermore, studies using Drosophila as a model system 
demonstrate that the loss of axonal mitochondria promotes tau phosphorylation and 
enhances tau-mediated neurodegeneration (23). The relationship between mitochondrial 
dysfunction and tau pathology is further supported by a recent work linking 
mitochondrial dynamics to tau toxicity in neurons (24).  
Notably, it has been reported that tangle-bearing neurons contain increased levels of 
free cholesterol than adjacent tangle-free neurons (25). The presence of AD-type NFTs 
is also a distinctive feature of the hereditary neurodegenerative disorder Niemann-Pick 
type C disease (NPC) (26), characterized by a defect in cellular cholesterol trafficking 
that lead to accumulation of unesterified cholesterol and other lipids, in particular 
sphingolipids, in late endocytic organelles and mitochondria (5, 27). Further studies in 
mouse models of NPC confirmed that cholesterol deregulation is a key pathogenic event 
affecting tau homeostasis in parallel with amyloid accumulation (28-30). Recently, the 
overexpression of APP in Npc1-deficient mice has been shown to accelerate the 
behavioral and neuropathological abnormalities characteristic of these mice, whereas 
treatment with β-cyclodextrin that significantly reduces brain cholesterol levels, 
increases longevity and attenuates pathological markers, therefore defining a functional 
mechanism shared by AD and NPC, and regulated by cholesterol (31). 
Tau hyperphosphorylation has also been described in apolipoprotein E deficient mice 
fed with high cholesterol diet (32, 33). 
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Unfortunately, it has been challenging to develop genetically engineered mouse 
models that recapitulate all of the neuropathological hallmarks of the disease. For 
example, unlike humans, the expression of amyloid precursor protein (APP) and 
presenilin (PS) mutant variants in mice has proved to be insufficient to promote NFTs 
and overt neurodegeneration (18, 34). To overcome this limitation, mice harboring 
human tau mutations associated to frontotemporal dementia have been extensively used 
to study neurofibrillary pathology, despite the absence of linkage of these mutations to 
AD in humans. However, tau involved in NFT is invariably wild type in AD, and hence 
a trustable model of AD-like tau pathology remains still elusive. 
Based on these data it is likely that alterations in intracellular cholesterol content could 
influence tau pathology by promoting tangle formation without the presence of 
pathogenic mutations in tau, and therefore accelerate AD-like pathology progression. To 
test this hypothesis, here we have generated APP/PS1 mice that constitutively 
overexpress the active truncated form of sterol regulatory element-binding protein-2 
(SREBP-2).  APP/PS1/SREBP-2 mice have increased brain cholesterol levels 
associated with a selective depletion of mGSH. Compared to APP/PS1 mice, triple 
transgenic mice display enhanced neuroinflammation, increased oxidative stress 
damage, and neuronal death associated to cognitive decline. Several tau kinases are 
activated in these mice, leading to hyperphosphorylated tau and NFT formation. 
Moreover, in vivo treatment of APP/PS1/SREBP-2 mice with GSH ethyl ester, that 
restores the pool of mGSH and prevents oxidative stress, has a direct impact on tau 
pathology and amyloid plaques, and results in less synaptic degeneration. These data 
provide evidence for the relevance of preserving the mitochondrial antioxidant defence 
as a therapeutic strategy in AD.   
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RESULTS 
Triple transgenic mice exhibit mitochondrial cholesterol loading and accelerated 
β-secretase activation and Aβ accumulation  
To analyze how overexpression of SREBP-2 modulates the course of different AD-
related pathological hallmarks triggered by brain accumulation of cholesterol, we 
generated a triple transgenic model harboring the human Swedish mutant APP(Swe), 
the human mutant PS1(∆E9), and the human SREBP-2 transgenes.  In line with 
previous observations in SREBP-2 mice (5), the triple transgenic mice displayed 
increased cholesterol levels, both in total brain extracts and in the mitochondrial 
fraction, associated with a selective depletion of mGSH levels at all the ages analyzed 
(Table 1), while the total GSH content in brain remained unaltered across all the 
genotypes (data not shown). Similar increases of cholesterol, either in total brain and 
mitochondria, with the subsequent mGSH depletion was also noticed in 10-month-old 
APP/PS1 mice, consistent with previous findings suggesting that Aβ metabolism 
regulates cholesterol homeostasis (1, 13, 14). 
In accordance with the notion that cholesterol potentiates the amyloidogenic processing 
of APP and Aβ generation (9-11), 4-month-old APP/PS1/SREBP-2 mice exhibited 
increased β-secretase activity (Fig. 1A) and immunohistological staining of diffused Aβ 
depositions in hippocampus (Fig. 1B) as well as increased incidence of high human Aβ 
(1-42) levels (Fig. 1C), which further increased at 7 and 10 months of age. These 
changes, however, lagged behind in APP/PS1 mice being detectable at 7 months of age 
(Fig. 1A-C). Similar results were observed when the levels of endogenous Aβ were 
analyzed (Supplemental Material, Fig. S1). Importantly, no activation of β-secretase 
or high levels of Aβ was observed in SREBP-2 transgenic mice (Fig. 1A and 
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Supplemental Material, Fig. S1), indicating that the elevation of brain cholesterol per 
se is not sufficient to trigger Aβ synthesis and accumulation. 
Exacerbated oxidative stress and neuroinflammation in APP/PS1/SREBP-2 mice 
We next analyzed markers of oxidative stress. Protein oxidation was enhanced in 
APP/PS1/SREBP-2 mice, exhibiting an age-dependent increase of protein 
carbonyl groups analyzed either spectrophotometrically (Fig. 2A) and by western blot 
(Supplemental Material, Fig. S2). Overexpression of SREBP-2 in APP/PS1 mice also 
resulted in increased oxidative DNA damage determined by 8-hydroxyguanosine 
immunostaining of hippocampus from 7-month-old mice (Fig. 2B). Associated with the 
oxidative damage we observed an age-dependent rise of the inflammatory cytokine 
interleukine-1 beta (IL-1β) in APP/PS1/SREBP-2 mice (Fig. 2C). The increment of IL-
1β expression was also detectable in SREBP-2 and APP/PS1 mice at older ages (Fig. 
2C).  The accelerated neuroinflammation displayed by the triple transgenic mice was 
further confirmed by immunohistochemical analysis of glial fibrillary acidic protein 
(GFAP) indicating enhanced astrogliosis in hippocampal samples from 7- and 10-
month-old mice (Fig. 2D and Supplemental Material, Fig. S3).  Microglial activation 
preceded astrogliosis in APP/PS1/SREBP-2 mice with increased presence of F4/80 
positive cells already detectable at 4 month of age (Fig. 2D). Quantitation of the area 
occupied by the immunoreactive glial structures also revealed a significant gliosis in 7-
month-old SREBP-2 and APP/PS1 mice but to a much lesser extent than in those of 
triple transgenic mice (Fig. 2E). 
Overexpression of SREBP-2 promotes synaptotoxicity and neuronal death in 
APP/PS1 mice 
Despite the fact that neuronal loss is a key feature of human AD, cell death is limited in 
most mouse models of β-amyloidosis and become only evident in older specimens. 
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Particularly, in APP/PS1 mice, the presence of apoptotic markers and hippocampal 
neuronal loss has been reported in brain sections from 16-month-old onwards (35, 36). 
In contrast, our previous studies using mouse models of cholesterol loading described 
an age-independent and enhanced susceptibility to Aβ neurotoxicity, resulting from an 
accumulation of cholesterol in mitochondria that favoured Aβ-induced cell death due to 
mGSH depletion (5). In line with these data, we observed that overexpression of 
SREBP-2 in APP/PS1 mice accelerated the decline of the presynaptic marker 
synaptophysin, starting at 4 months of age with further progression in 7- and 10-month-
old mice (Fig. 3A), whereas this outcome was only significant in 10-month-old 
APP/PS1 mice (Fig. 3A). Moreover, the increased synaptic degeneration displayed by 
APP/PS1/SREBP-2 mice was accompanied with a marked neuronal death analyzed by 
Fluoro-Jade B staining (Fig. 3B) and TUNEL assay (Fig. 3C) in hippocampal CA1 
regions of 10-month-old mice. In contrast, at this age signs of neuronal damage were 
almost negligible in APP/PS1 mice (Fig. 3B and C).  Taken together, these 
observations emphasize the key role of cholesterol in regulating the neurodegenerative 
process. 
SREBP-2 overexpression in APP/PS1 mice impairs short-term recognition 
memory but does not worsen spatial memory deficits 
To determine whether the increased neuronal damage observed in the triple transgenic 
mice can influence cognitive performance, we evaluated spatial memory acquisition and 
retention abilities in all four groups at 7 month of age. We first analyzed the 
performance of mice in a non-spatial cued platform variant of the Morris water maze 
(MWM). As seen, all the groups exhibited similar escape latencies to the visible 
platform indicating no differences in vision and motivation (Fig. 4A). When the spatial 
hippocampus-dependent MWM was tested, all mice exhibited similar escape latencies 
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to the hidden platform (Fig. 4A) indicating that the learning kinetics during the 
acquisition phase were similar among the groups. Conversely, in the probe trial when 
the platform was removed, one-way ANOVA indicated significant changes in the time 
the mice spent in the target quadrant, while wild-type (WT) and SREBP-2 transgenic 
mice preferred the target quadrant, APP/PS1 mice showed no preference for the target 
quadrant relative to the other three quadrants (Fig. 4B). The impaired memory retention 
displayed by the APP/PS1 mice was unaffected by SREBP-2 overexpression (Fig. 4B). 
These differences cannot be accounted for motor deficits, as the swim speeds across all 
four genotypes were equivalent (Fig. 4C). Mice were also tested using the object 
recognition paradigm, a behavioural task mainly dependent on cortical areas, including 
the perirhinal cortex (37, 38). This test exploits the natural tendency of mice to explore 
objects perceived as novel. We found that whereas recognition memory in WT, SREBP-
2 and APP/PS1 mice was intact (Fig. 4D), triple transgenic mice failed to discriminate 
between novel and familiar objects (Fig. 4D). The impairment in object recognition 
memory in addition to the spatial memory deficits displayed by APP/PS1/SREBP-2 
mice may therefore reflect a wider brain area affected relative to that in APP/PS1 mice, 
implying that brain deterioration in triple transgenic mice expands to the perirhinal 
cortex in addition to hippocampus. 
SREBP-2 overexpression in APP/PS1 mice enhances the development of tau 
pathology.  
Abnormal tau hyperphosphorylation and aggregation is present in NPC (26) and 
treatment with the cholesterol-lowering drug 2-hydroxypropyl-β-cyclodextrin 
significantly attenuates the neurofibrillary pathology in NPC patients and animal 
models (31, 39), therefore, suggesting a link between cholesterol and tauopathy. Based 
on these observations, we analyzed the phosphorylation status of tau in triple transgenic 
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mice. In particular, we focused on phospho Ser-396 and phospho Ser-202/ Thr-205 
(AT8) residues, as these have been widely used for the detection of NFTs in AD. 
APP/PS1/SREBP-2 displayed an age-dependent increase in phospho Ser-396 starting at 
4 month of age and high AT8 immunoreactivity detectable at 4 and 10 month of age 
(Fig. 5A), while tau phosphorylation (AT8 immunoreactivity) was significant in 10-
month-old APP/PS1 mice (Fig. 5A). Levels of total tau (tau-5) were unchanged in all 
the groups and at all the ages analyzed (Fig. 5A). Since tau phosphorylation can result 
in disruption of microtubule stability and formation of insoluble tau aggregates, we 
evaluated the solubility of tau by fractionation of crude extracts with sarkosyl. Western 
blot analyses revealed sarkosyl-insoluble tau accumulation exclusively in brain extracts 
from APP/PS1/SREBP-2 mice (Fig. 5B). To assess whether the insoluble tau content in 
triple transgenic mice undergo structural changes resembling NFT, sections of 
hippocampus from 10-month-old mice were examined with Gallyas silver and 
thioflavin S stains (Fig. 5C). Significantly, APP/PS1/SREBP-2 mice showed increased 
number of Gallyas-positive inclusions compared to APP/PS1 mice, which were also 
stained with the amyloid-specific dye thioflavin S (Fig. 5C). Additionally, we 
performed immunohistochemistry of hippocampal slices from 10-month-old 
APP/PS1/SREBP-2 mice, using the phospho-dependent anti-tau antibody AT8 in 
combination with different brain cell type-specific markers (Supplemental Material, 
Fig. S4). The confocal analyses confirmed that hyperphosphorylated tau specifically co-
localized with the neuronal marker microtubule-associated protein 2 (MAP2), forming 
small aggregates mainly within the somatodendritic compartments. Although glial 
fibrillary tangles have been reported in AD (40), no co-localization was observed 
between AT8 and GFAP or myelin basic protein (MBP), therefore, discarding the 
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presence of tau inclusions in astrocytes and oligodendrocytes (Supplemental Material, 
Fig. S4). 
APP/PS1/SREBP-2 mice exhibit activation of kinases involved in tau 
phosphorylation 
We next analyzed the activity profile of various protein kinases implicated in tau 
phosphorylation, including glycogen synthase kinase-3 beta (GSK-3β), cyclin-
dependent kinase 5 (CDK5), and the family members of mitogen-activated protein 
kinase (MAPK): extracellular signal-regulated kinase 1/2 (ERK 1/2), stress-activated 
protein kinase/Jun-amino-terminal kinase (SAPK/JNK) and p38 MAPK. As an 
indication of the activity, we determined the ratio of the immunoreactivity of the active 
phosphorylated form and the total level of each kinase (Supplemental Material, Fig. 
S5). As seen, the 3 MAPK examined were activated in APP/PS1/SREBP-2 mice (Fig. 
6A), with an early phosphorylation of p38 MAPK beginning at 4 months of age, 
followed by phosphorylation of SAPK/JNK and ERK 1/2 at latter age. In contrast, 
APP/PS1 mice showed a significant activation of SAPK/JNK by 7 month of age (Fig. 
6A). As for GSK-3β, both the active (phospho Tyr-216) and the inactive (phospho Ser-
9) forms were investigated (Fig. 6B). APP/PS1/SREBP-2 mice showed an age-
dependent increase of phosphorylated Tyr-216, starting at 7 months of age. Associated 
with this increase we observed a reduction of the inhibitory Ser-9 phosphorylation, 
which was already evident in 4-month-old mice (Fig. 6B). In APP/PS1 mice levels of 
phospho Ser-9 decreased at 10 month of age but did not correlate with a significant 
increase in phospho Tyr-216. SREBP-2 overexpression in APP/PS1 mice also promoted 
the activation of CDK5 at all ages (Fig. 6C), reflected by phosphorylated CDK5 and 
increased conversion of p35 to p25, the neuronal activator of CDK5, in brain from 7- 
and 10-month-old APP/PS1/SREBP-2 mice. Total CDK5 levels were not significantly 
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different between the four genotypes (Fig. 6C). Since it has been reported a connection 
between loss of function of protein phosphatase 2A (PP2A) and tau 
hyperphosphorylation (41) we checked the expression of the catalytic C subunit of the 
enzyme and the levels of phosphorylated PP2A C at Tyr307, which inhibits the enzyme 
activity (Fig. 6D). As seen, total levels of PP2A C subunit remained unaltered in the 
four groups and at all ages (Fig. 6D). Additionally, the degree of phosphorylation-
dependent inhibition was similar between groups, with an age-dependent tendency to 
decrease in all genotypes. Taken together these observations provide evidence that 
cholesterol regulate tau phosphorylation by promoting the activation of several tau 
kinases and discard a contributory role of phosphatases in this event. 
Increased proteolytic cleavage of tau protein in mice harboring the SREBP-2 
transgene 
Toxic tau aggregation can be accelerated by proteolytic cleavage (42). Cleaved tau 
serves as a nucleation center for the pathological assembly of tau filaments. 
Consequently, cellular conditions that increase tau levels and fragmentation could favor 
formation of NFT. Since recent evidences suggested that cholesterol can indirectly 
promote tau fragmentation by modulating the activity of several proteases, including 
calpain and cathepsin D (31, 43, 44), we investigated the generation of cleaved tau 
fragments in the triple transgenic mice (Fig. 7A). Total levels of tau remained almost 
unchanged between all the genotypes; however, when films were over-exposed we 
observed the presence of cleaved tau fragments in APP/PS1/SERBP-2 mice by 4 month 
of age. Interestingly, despite absence of NFT (Fig. 5B and C), brain extracts from 
SREBP-2 mice also showed fragmented tau (Fig. 7A), suggesting that cleavage of tau 
triggered by cholesterol is not sufficient to promote tau aggregation and toxicity. Next, 
we checked cleavage of α-spectrin into calpain specific signature fragments as a marker 
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of calpain activity (Fig. 7B). As seen, calpain-cleaved spectrin immunoreactivity and 
the subsequent quantification of the 150/145 to 240 kDa spectrin ratio in brain lysates  
indicated increased calpain activation in all 3 groups of mutant mice (SREBP-2, 
APP/PS1 and APP/PS1/SREBP-2 mice) compared to WT mice (Fig. 7B). The levels 
and activity of the lysosomal aspartic peptidase cathepsin D were also analyzed (Fig. 
7C). We observed an up-regulated expression of the immature form of cathepsin D (48 
kDa) in all 3 mutant mice, however, the ratio between mature and immature forms (33/ 
48 kDa ratio) revealed an enhanced processing only in brain from mice that overexpress 
SREBP-2 (Fig. 7C).  Although maturation seemed to be promoted by high levels of 
cholesterol, the increased levels of mature cathepsin D did not ultimately translate into a 
significant increase of enzyme activity (Fig. 7D). Therefore, these data suggest that 
neither calpain nor cathepsin D is responsible for tau cleavage in mice that carry the 
SREBP-2 transgene. The enhanced maturation of cathepsin D in these mice is more 
likely a compensatory response to an impaired endolysosome system, as previously 
reported using rabbits fed with a cholesterol-enriched diet (45), and hence, further work 
would be needed to elucidate the exact mechanism.  
Recovery of mGSH by in vivo GSH ethyl ester treatment reduces tau pathology 
and prevents amyloid plaques formation in APP/PS1/SREBP-2 mice. 
Since reactive oxygen species (ROS) can regulate major cellular signalling pathways, 
and particularly the activity of some members of the MAPK cascade (46) we next 
probed the potential mechanistic link between increased oxidative stress and the 
progression of tau pathology in APP/PS1/SREBP-2 mice by treating mice with the cell-
permeable derivative GSH ethyl ester (GSHee) (i.p. 1.25 mmol/kg/day, every 12 h for 2 
weeks) (Fig. 8). As seen, GSHee administration significantly recovered the 
mitochondrial pool of GSH (Fig. 8A) and reduced the protein carbonyl content in brain 
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from 7-month-old APP/PS1/SREBP-2 mice (Fig. 8B). Associated to this lower 
oxidative damage we found decreased levels of phosphorylation in all the three MAPK 
analyzed, namely SAPK/JNK, ERK 1/2 and p38 MAPK (Fig. 8C), whereas the degree 
of phosphorylation in GSK-3β and CDK5 was unaltered in APP/PS1/SREBP-2 mice 
after GSHee administration (Fig. 8D).  Interestingly, the inactivation of MAPK in the 
triple transgenic mice after mGSH recovery was sufficient to reduce the levels of tau 
phosphorylation at Ser-396 (Fig. 8E) and tau aggregation, with decreased levels of 
sarkosyl-insoluble tau in APP/PS1/SREBP-2 mice treated with GSHee (Fig. 8F). 
Previous experimental data indicated that oxidative stress can also modulate amyloid 
plaque pathology (47-49). We first examined whether mGSH recovery had any impact 
on the amyloidogenic processing of APP (Fig. 8G). As seen, levels of APP β-C-
terminal fragments (β-CFTs) remained unchanged in the triple transgenic mice after 
GSHee treatment. However, GSHee significantly lowered the amyloid deposition 
detected by Aβ (1-42) antibody staining in hippocampal slices from APP/PS1/SREBP-2 
mice (Fig. 8H and J). Similar degree of amyloid burden reduction was observed with 
thioflavin S staining (Fig. 8I and J). Since thioflavin S can also recognize and bind β-
sheet pleated tau fibrils we analyzed the images at higher magnification (Supplemental 
Material, Fig. S6) and found that GSHee treatment reduced the presence of thioflavin-
positive structures in the pyramidal cell layers of the hippocampus was significantly 
reduced after GSHee administration. Moreover, the analyses of synaptophysin 
immunoreactivity showed that GSHee administration was able to significantly prevent 
the synaptic degeneration observed in triple transgenic mice at 7 months of age (Fig. 
8K). Overall these data show that alterations in brain cholesterol levels directly impact 
on AD progression. Mitochondrial oxidative stress can control tau phosphorylation via 
MAPK activation and cholesterol-induced mGSH depletion arises as a key pathogenic 
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factor in AD, at least in part, by promoting tau pathology and Aβ deposition.
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DISCUSSION 
Although cumulating evidence indicates that cholesterol can regulate Aβ accumulation 
and neurotoxicity, our current understanding of the underlying mechanisms and impact 
on AD is still incomplete. Here, we have generated a new AD mouse model that 
provides a unique tool to examine the age-dependent contribution of increased 
cholesterol in the onset of AD-like pathological alterations. A key feature of the triple 
transgenic model is the combined exhibition of amyloidogenic APP processing leading 
to Aβ generation and tau pathology due to SREBP-2 expression. Moreover, SREBP-2 
expression in APP/PS1 mice accelerates and worsens brain oxidative damage and 
neuroinflammation, with an enhanced age-dependent synaptic degeneration already 
detectable in 4-month-old mice and neuronal death observed at 10 months of age. This 
outcome translated in spatial and object-recognition memory deficits, indicating a 
functional deterioration of perirhinal cortex and hippocampus. 
Since triple transgenic mice exhibited stimulated Aβ synthesis and deposition in 
hippocampus at 4 months of age, much earlier than APP/PS1 mice, it could be 
speculated that the accelerated pathology observed in these mice is a merely 
consequence of increased amyloidogenesis. However, the fact that only APP/PS1 mice 
that carry the SREBP-2 transgene displayed frank neurodegeneration and recognition 
memory impairment at the age of 10 months, despite similar Aβ accumulation between 
APP/PS1 mice and triple transgenic mice, suggests the existence of other contributory 
mechanisms.  
Associated to changes in brain cholesterol levels APP/PS1/SREBP-2 mice showed 
depleted mGSH. Therefore, given the key role of mGSH in controlling the oxidative 
stress generated in mitochondria (50), and based in our previous works that described an 
increased sensitivity to Aβ toxicity by mGSH-depleted cells (5, 17), we hypothesized 
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that a critical culprit in the neuronal death observed in the triple transgenic mice resulted 
from this compromised mitochondrial antioxidant defense. Additionally, recent studies 
suggest that mitochondrial dysfunction can promote tau hyperphosphorylation and 
neurodegeneration (22, 51). Furthermore, tangle pathology rather than Aβ burden has 
been shown to correlate better with AD severity (52, 53). While APP/PS1 mice do not 
exhibit the full spectrum of neurodegeneration, cognitive decline associated with 
synaptic dysfunction and neuronal loss has been reported in animal models expressing 
pro-aggregant tau (54, 55). Furthermore, in these mice tau-mediated toxicity is 
reversed when aggregation is avoided (54, 55). Remarkably, unlike other AD mouse 
models that require the expression of mutant human tau (56), we provide evidence that 
APP/PS1/SREBP-2 mice developed full tau pathology.  
A link between cholesterol and tau pathology reflected by NFT has been previously 
observed in brains from individuals affected by the lipid storage disorder NPC (57, 58). 
Further studies in mouse models of NPC show that impaired cellular cholesterol 
trafficking is associated with enhanced generation of Aβ and the hyperphosphorylation 
of tau, mirroring AD pathology (28, 39, 59). Conversely, treatment with cyclodextin 
ameliorates Aβ and tau alterations, resulting in delayed neurodegeneration and 
increased lifespan of NPC mice (31, 60, 61). In the same line, we observed an early 
phosphorylation of endogenous tau in epitopes linked to tangle formation associated 
with presence of Gallyas/thioflavin S positive neurons in the hippocampus of 
APP/PS1/SREBP-2 mice, indicative of AD-type NFTs. Evidence to support this 
outcome included the presence of sarkosyl-insoluble tau accumulation reflecting the 
onset of tau aggregates. Moreover, using a phospho-specific tau antibody we showed 
that these structures accumulate in the somatodendritic compartment of hippocampal 
neurons, in agreement with previous reports describing a missorting of tau from the 
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normal axonal localization to somatodendritic sites in AD brain (62, 63). Whether tau 
inclusions are toxic, interfere in essential cell processes or trigger neurite degeneration 
by decreasing microtubule stabilization is still under debate. Moreover, a growing body 
of evidence also point to pre-tangle tau species (soluble monomers or oligomers) as the 
main responsible for toxicity in tauopathies (64). Therefore, further research is needed 
to understand the exact mechanisms by which tau contributes to disease. 
SREBP-2 transgenic mice did not develop NFTs, indicating that the rise of cholesterol 
levels and its trafficking to mitochondria to elicit mGSH depletion per se are not 
sufficient to promote tau hyperphosphorylation and aggregation. Many studies have 
previously reported the potentiation of tau pathology by Aβ, positioning tau 
abnormalities downstream of Aβ in AD (20, 65, 66). Accordingly, our results show that 
generation of Aβ and mitochondrial cholesterol-induced mGSH depletion are required 
for the oxidative stress-mediated activation of tau kinases, particularly, MAP kinases, 
which in turn participate in the cascade of events leading to tau aggregation. In line with 
this scenario, mGSH recovery by GSH ethyl ester prevented MAP kinases activation 
and tau phosphorylation in triple transgenic mice. Although CDK5 and GSK3β were 
also activated in APP/PS1/SREBP-2 mice their activity, unlike that of MAP kinases, 
remained unaltered after blocking Aβ-induced oxidative stress by GSH ethyl ester 
treatment. Recent evidence indicates that both CDK5 and GSK3β are activated on 
cellular membranes, and thus deregulation of sterol may somehow modulate their 
activity by poorly understood mechanisms (67, 68). Moreover, we did not find changes 
neither in the phosphorylation state nor in the expression of the catalytic subunit of the 
PP2A, indicating that although cholesterol may stimulate tau kinases activation, 
phosphatase activity is not influenced by cholesterol load, as previously described (33), 
and hence suggesting a minor role of PP2A in cholesterol-induced tau pathology. 
20 
 
Quite intriguingly, the levels of brain cholesterol in 10 month-old APP/PS1 mice were 
similar to those observed in the triple transgenic mice. Yet, only the latter exhibited tau 
pathology and neurodegeneration. Perhaps a key clue to this apparent riddle may 
involve the different mechanism of cholesterol accumulation between APP/PS1 mice 
driven by Aβ and the triple transgenic mice due to SREBP-2 expression. While Aβ-
mediated cholesterol regulation involves low density lipoprotein receptor-related protein 
1 (14), SREBP-2 is a key transcription factor regulating the synthesis of cholesterol in 
the mevalonate pathway (69). In addition to synthesizing cholesterol, the mevalonate 
pathway is also essential in the generation of isoprenoids and hence in protein 
prenylation, a key posttranslational mechanisms of proteins. While targeting protein 
prenylation has been shown to be of potential relevance in cancer cell biology (70), 
emerging evidence reports alteration in the regulation of isoprenoids farnesyl- and 
geranylgeranylpyrophosphate (GGPP) in patients with AD (71). Moreover, recent data 
in a cellular model of tauopathy show that statin-induced inhibition of GGPP decreases 
phosphorylated tau levels by affecting GSK3β activity (72). Hence, it is conceivable 
that triple transgenic mice exhibit increased protein prenylation with respect to 
APP/PS1 that may contribute to tau pathology.   High circulating cholesterol levels in 
APP/PS1/SREBP-2 mice might also play an additive role as treatment with different 
types of statins has been described to reduced NFT severity regardless of the capability 
to cross the blood-brain barrier (73). 
APP/PS1 mice exhibit spatial memory deficits in the absence of neuronal loss and in 
agreement with previous reports showing a correlation between the degree of cognitive 
impairment and synaptic dysfunction (74). Moreover, when we analyzed the 
contribution of cholesterol in cognition we observed that SREBP-2 overexpression in 
APP/PS1 mice did not worsen the loss of spatial memory retention but impaired novel 
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object recognition ability. Interestingly, this short-term recognition memory mainly 
relays on the perirhinal cortex (37, 38). Furthermore, histological studies and magnetic 
resonance image analysis demonstrate that pathological changes involve the entorhinal 
and perirhinal cortex early in the course of the disease (75, 76), with NFTs described to 
first develop in these brain areas before spreading to the hippocampus (75, 77). 
Recently, different reports using specific mitochondria-targeted antioxidants suggest 
that protection of mitochondrial function is sufficient to prevent AD-like 
neuropathology (78, 79). Our in vivo treatment with GSH ethyl ester further supports a 
central role of mitochondrial oxidative stress in the neurodegenerative process. We 
found that administration of GSH ethyl ester to APP/PS1/SREBP-2 mice for 2 weeks 
was sufficient to recover the pool of mGSH resulting in significant reduction in the 
carbonyl protein levels. Associated to this decreased oxidative damage we observed an 
improvement in tau pathology and increased synaptophysin levels, indicative of 
synaptic recovery. Moreover, our findings are consistent with previous studies in 
Tg19959 mice showing that overexpression of the mitochondrial antioxidant enzyme 
manganese superoxide dismutase reduces amyloid plaque burden without alteration in 
amyloidogenic processing (49). In addition, although tau pathology was not addressed 
in these mice, synaptophysin levels and spatial memory deficits were restored to WT 
levels (49). Based on recent findings indicating that mGSH determines the therapeutic 
potential of superoxide anion scavenging in steatohepatitis (80), it remains to be 
established whether the beneficial effects of MnSOD overexpression in Tg19959 mice 
was dependent on mGSH levels. Overall, our results provide novel  insights into the 
relationship between cholesterol and the disease progression, underlining the key 
contributory role of an impaired cholesterol homeostasis in tau pathology and consistent 
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with recent studies, providing evidence for the use of mitochondria-targeted 
therapeutics directed to protect the mitochondrial antioxidant defense. 
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MATERIALS AND METHODS 
APP/PS1 and SREBP-2 mice 
Breeding pairs of B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J and B6;SJL-
Tg(rPEPCKSREBF2)788Reh/J were purchased from The Jackson Laboratory. 
APP/PS1/SREBP-2 mice were generated from crossbreeding SREBP-2 and APP/PS1 
mice, which were first back-crossed more than 5 generations into the B6SJL 
background. At the time of weaning (21 d), mice were genetically identified by PCR 
using DNA from ear-tips and following the genotyping protocols provided by the 
supplier. Male mice at the indicated ages of different genotypes used in a given 
experiment were obtained from the same breeding pairs. All procedures involving 
animals and their care were approved by the ethics committee of the University of 
Barcelona and were conducted in accordance with institutional guidelines in compliance 
with national and international laws and policies.   
Mitochondrial isolation  
Cerebral cortices were isolated and homogenized in 210 mM mannitol, 60 mM sucrose, 
10 mM KCl, 10 mM sodium succinate, 1 mM ADP, 0.25 mM DTT, 0.1 mM EGTA, 10 
mM HEPES, pH 7.4. Homogenates were centrifuged at 700g for 10 min, with the 
recovered supernatant being centrifuged at 10,000g for 15 min. The resulting pellet was 
suspended in 2 ml, loaded onto 8 ml of 30% (v/v) percoll gradient and centrifuged at 
95,000g for 30 min. The mitochondrial pellet was then rinsed twice by centrifuging 15 
min at 10,000g. 
GSH and Cholesterol measurements 
GSH levels in homogenates and mitochondria were analyzed by the recycling method 
(81). For cholesterol determination, samples were extracted with alcoholic KOH, 
distilled water and hexane (1:1:2, v/v/v). Appropriate aliquots of the hexane layer were 
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evaporated and used for cholesterol measurement (82). HPLC analysis was made using 
a Waters μBondapak C18 10 μm reversed-phase column (30 cm x 4 mm inner 
diameter), with the mobile phase being 2-propanol/acetonitrile/distilled water (6:3:1, 
v/v/v) at a flow rate of 1 ml/min. The amount of cholesterol was calculated from 
standard curves and the identity of the peaks was confirmed by spiking the sample with 
known standards. 
β-secretase activity, cathepsin D activity and Aβ levels 
β-secretase and cathepsin D activities were analyzed spectrofluorometrically using 
commercial assay kits from Abcam. Levels of endogenous or human recombinant Aβ1-
42 peptide in brain extracts were determined in duplicate using the colorimetric mouse 
and human Aβ1-42 ELISA kits (Biosource International) following the manufacturer’s 
instructions. 
Carbonyl protein levels  
Protein carbonylation was estimated using the OxyblotTM protein oxidation detection kit 
(Chemicon) according to the manufacturer’s instructions. Briefly, the carbonyl groups 
in the protein side chains were derivatized by reaction with 2,4-dinitrophenylhydrazine 
(DNPH) and the DNP derivatives were analyzed by western blotting. In parallel, 
samples were examined spectrophotometrically using the OxiSelectTM protein carbonyl 
spectrophotometric assay kit (Cell Biolabs). 
Western blot analysis  
Samples (30-80 μg of protein / lane) were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes. Blots were probed with antibodies listed in Table 2. After 
overnight incubation at 4ºC, bound antibodies were visualized using horseradish 
peroxidase-coupled secondary antibodies and ECL developing kit (Amersham 
Biosciences). Densitometry of the bands was measured with QuantityOne software and 
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values were normalized to β-actin or glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). 
Sarcosyl insoluble tau was isolated based on the modified method of Greenberg and 
Davies (83).  Brain tissue was homogenized in tris-buffered saline (TBS), a small 
sample was removed for the analysis of total tau and the remainder was centrifuged at 
100,000g for 60 min at 4ºC. The pellet was homogenized in 0.8 M NaCl and 10% 
sucrose in TBS. After centrifugation at 150,000g for 15 min, the supernatant was 
brought to 1% sarkosyl and incubated at 37ºC for 1 hour. The mixture was then 
centrifuged at 150,000g for 30 min and the precipitate was collected as the sarkosyl-
insoluble fraction.  
Immunohistochemistry  
Cryopreserved (10 µm) or paraffin (5 µm) sections from –1.2 mm through –2.4 mm 
from Bregma were processed according to the avidin–biotin–peroxidase staining 
method (Vectastain ABC kit; Vector Lab.). Tissues processed for Aβ staining were 
pretreated with 99% formic acid for 7 min. After antigen retrieval treatment, the 
endogenous peroxidase was blocked by exposure to 3% H2O2 in methanol for 30 min. 
The sections were treated with the Avidin/Biotin blocking kit from Vector Lab 
according to the manufacturer’s instructions and incubated overnight at 4ºC with 
antibodies listed in Table 2. After washing with PBS, sections were then incubated for 1 
h with appropriated biotinylated secondary antibodies at a dilution of 1:400, followed 
by ABC staining for 1 h. The immunoreaction was visualized with diaminobenzidine 
(DAB enhanced liquid substrate system, Sigma). Sections were counterstained with 
hematoxylin (Dako). Presence of neurofibrillary tangles was detected by Gallyas silver 
staining. To analyze presence of β-sheet-rich structures sections were stained in 1% 
Thioflavine S for 5 min, and differentiated with 70% ethanol for 5 min. To detect DNA 
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fragmentation, terminal deoxynucleotidyl transferase-mediated uridine 5′ -triphosphate-
biotin nick end-labeling (TUNEL assay) was performed according to the manufacturer 
recommendations (In Situ Cell Death Detection Kit, TUNEL POD, Roche Applied 
Science). Neuronal degeneration was also assessed by staining sections with Fluoro-
Jade B (0.0004 %, Chemicon) (84).  
Immunofluorescence and laser confocal imaging  
Dewaxed hippocampal sections were first boiled in citrate buffer (10 mM sodium citrate 
pH 6.0) and incubated with 0.1 M glycine / PBS for 20 min to reduce autofluorescence. 
The sections were incubated overnight at 4°C with antibodies listed in Table 2. After 
washing in PBS, antibody staining was visualized using Alexa 488- and Cy3-coupled 
secondary antibodies (1:400; Invitrogen and Jackson ImmunoResearch Inc.). In some 
cases, nuclei were stained with Hoechst 33258 (2 µg / ml) before mounting the samples 
in Fluoromount-G (Southern Biotech). Confocal images were collected using a Leica 
TCS SPE laser scanning confocal microscope equipped with UV excitation, an argon 
laser, a 633/1.32 OIL PH3 CS objective and a confocal pinhole set at 1 Airy unit. All 
the confocal images shown were single optical sections. For GFAP and F4/80 integrated 
density analysis, nonsaturated images from equivalent regions were analyzed with 
ImageJ software to quantify integrated density staining per relevant area within each 
image for each replicate. Threshold adjustments were set to ensure quantification of 
only positive immunostaining. 
Real-time RT-PCR  
Total RNA was isolated from brain with the TRIzol reagent (Invitrogen). Real-time 
PCR amplification for IL-1β was performed using the iScript™ One-Step RT-PCR Kit 
with SYBR® Green (Bio-Rad) following the manufacturer’s protocol. Briefly, 20 ng of 
total RNA, 600 µmol/l of primers, and 12.5 µl of 2X reaction mix were incubated in 25 
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µl at 50 °C for 10 min and 95 °C for 5 min, followed by 45 cycles of 95 °C for 10 s, 56 
°C for 30 s, and 72 ºC for 30 s. Each reaction was run in duplicate and the threshold 
(CT) values for each mRNA were subtracted from that of 18S mRNA, averaged and 
converted from log-linear to linear term. The primers used were: IL-1β forward 5’-
GAGCTGAAAGCTCTCCACCTC-3’; IL-1β reverse 5’-
CTTTCCTTTGAGGCCCAAGGC-3’; 18s forward 5’-GTAACCCGTTGAACCCCAT 
T -3’; 18s reverse 5’-CCATCCAATCGGTAGTAGCG -3’. 
Morris water maze  
Hippocampus-dependent spatial memory was examined using the Morris water maze 
(MWM) (85). Briefly, the water-maze pool (diameter, 100 cm) contained opaque water 
(23±1 °C) with a platform (diameter, 10 cm) submerged 1 cm. To evaluate the visual 
perception and motivation, mice were trained to locate first a cued platform (sessions 1 
and 2). To test reference memory, mice were trained using a hidden platform with four 
visual cues surrounding the pool of water and limiting the four quadrants (sessions 3-7). 
The platform was located in the center of one of the quadrants of the pool (target 
quadrant). Animals were allowed 60 s to locate the platform and 30 s to rest on it. Mice 
that failed to find the platform were placed on it and allowed to rest there for 30 s. The 
acquisition task consisted in 8 trials per day with 15 min inter-trial intervals. To assess 
spatial memory retention a single 60-s probe trial without platform was administered 1 h 
after the last hidden-platform session. Performance was recorded with an automated 
tracking system (SmartJunior) during all training and probe trials. The relative time 
spent in each of the four quadrants and the number of crossings of the former platform 
location were recorded and analyzed during the probe trials. 
Novel object recognition  
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The novel object recognition task, which uses cortical and hippocampal inputs was 
administered as described (86). During three consecutive days, mice were habituated to 
an empty open field (diameter, 40 cm) for 10 min. The fourth day, mice were allowed to 
explore two identical objects located equidistant from the walls and the center of the 
open field during 10 min. One hour later, the trial was repeated with one of the objects 
being replaced with a novel object of similar size. Time spent exploring the identical 
and novel objects was quantified. Between each trial, the open field was cleaned with 
70% ethanol to eliminate olfactory cues. An increased percentage of time spent 
exploring the novel object (duration spent with novel object/(duration spent with novel 
object + duration spent with familiar object) × 100) is considered an index of enhanced 
cognitive performance in this task.  
Statistics  
Results are expressed as means±SD of the number of experiments. Statistical 
significance was examined using the unpaired two-tailed Student’s t-test or one-way 
ANOVA with Dunnett’s or Bonferroni's post hoc multiple comparisons test when 
required. A p < 0.05 value was considered statistically significant. 
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FIGURE LEGENDS 
Figure 1. Increased cholesterol promotes Aβ synthesis and loading. (A) β-secretase 
activity analyzed in brain extracts from WT and transgenic mice (A.U.: arbitrary units). 
*P< 0.05, **P< 0.01 (n = 3). Values are mean ± S.D. (B) Representative 
photomicrographs of hippocampus labeled with human anti-Aβ(1-42) and 
counterstained with hematoxylin showing early Aβ depositions in APP/PS1/SREBP-2 
mice. Scale bar: 100 µm. (C) Brain from WT and indicated mutant mice (A/P: APP/PS1 
mice; A/P/S-2: APP/PS1/SREBP-2 mice) were homogenized with guanidine HCl 
extraction buffer, and the homogenates were analyzed by ELISAs for quantitative 
assessment of human Aβ(1-42) content at the indicated ages (n = 6 per genotype).  
Figure 2.  SREBP-2 overexpression in APP/PS1 mice exacerbates oxidative stress and 
neuroinflammation. (A) Protein carbonyl content from brain of the indicated genotype 
analyzed spectrophotometrically. *P< 0.05, **P< 0.01 (n= 6). (B) 
Immunohistochemical staining of 8-hydroxyguanosine (8-OHG). Representative 
photomicrographs of hippocampus showing nuclear presence of 8-OHG in 7-month-old 
APP/PS1-SREBP-2 mice as indicative of oxidative DNA damage. Scale bar: 100 µm. 
(C) mRNA levels of IL-1β in brain from indicated genotype analyzed by quantitative 
PCR. Absolute mRNA values were determined, normalized to 18S and reported as 
relative levels referred to the expression in WT mice. *P< 0.05 vs. WT values (n = 6). 
(D-E) Activation of astrocytes and microglia analyzed by GFAP and F4/80 
immunostaining, respectively.  (D) Representative confocal images of GFAP and F4/80 
immunofluorescence (red) of hippocampal sections from 7- and 4-month-old mice, 
respectively. Nuclei were stained with Hoechst 33258 (blue). Scale bar: 50 µm. (E) 
Quantification of GFAP (left axis) and F4/80 (right axis) immunoreactivity by 
integrated density analysis. *P< 0.01 (n = 6). Values are mean ± S.D. 
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Figure 3. APP/PS1/SREBP-2 mice exhibit enhanced neuronal damage. (A) 
Representative immunoblotting showing synaptophysin (synapt.) protein levels from 
WT and indicated mutant mice (S-2: SREBP-2 mice; A/P: APP/PS1 mice; A/P/S-2: 
APP/PS1/SREBP-2 mice). Densitometric values of the bands representing 
synaptophysin immunoreactivity were normalized with the values of the corresponding 
β-actin bands (O.D.: normalized optical density). *P< 0.05 vs. WT values (n = 3). 
Values are mean ± S.D. (B) Representative images of degenerated neurons in 
hippocampal regions from 10-month-old mice by Fluoro-Jade B staining. Scale bar: 100 
µm. (C) Representative images of apoptotic cells in hippocampus from 10-month-old 
mice by terminal deoxynucleotidyl transferase mediated nick-end labeling assay 
(TUNEL assay). Scale bar: 50 µm. 
Figure 4. SREBP-2 overexpression in APP/PS1 mice does not worsen the spatial 
memory deficits but impairs short-term recognition memory. Morris water maze 
(MWM) was used to evaluate the spatial memory deficits in 7-month-old mice (n = 10-
15 per genotype). (A) Cognitive performance in cued tasks (C1 and C2) and acquisition 
sessions (3-7) measured as mean time to locate the escape platform.  All mouse strains 
showed similar latencies to reach the platform in the nonspatial variant of the MWM 
(C1 and C2). Learning rates during spatial memory acquisition were similar between 
groups. (B) Performance in the probe trial measured as mean % time spent in target 
quadrant. APP/PS1 and APP/PS1/SREBP-2 mice showed no preference for the target 
quadrant relative to the other quadrants, whereas mice without APP/PS1 expression 
preferred the target quadrant. *P< 0.01, **P< 0.05. C, Swimming speed exhibiting no 
significant differences among groups. (D) Novel object recognition test was used to 
assess deficits in short-term recognition memory in 7-month-old mice (n = 7-12 per 
genotype). Shown is the recognition index, which is the amount of time exploring the 
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novel or familiar object versus the overall exploration time multiplied by 100. APP/PS1 
mice that overexpress SREBP-2 exhibited similar preference between novel and 
familiar objects. *P< 0.05 vs. WT values. Values are mean ± S.D. 
Figure 5. SREBP-2 overexpression in APP/PS1 mice enhances the development of 
neurofibrillary pathology. (A) Protein extracted from brain homogenates of WT and 
mutant mice at the indicated ages analyzed by western blot to assess phosphorylation 
levels of tau at different epitopes recognized by the indicated phosphorylation-
dependent and site-specific anti-tau antibodies. Total tau levels were detected by the 
phosphorylation-independent antibody Tau-5. (B) Protein immunoblots showing total 
(non-phosphorylated and phosphorylated) tau (Tau-5) in crude and sarcosyl-
insoluble fractions from brain homogenates of WT and mutant mice at the indicated 
ages. (C) Representative sections of hippocampus from 10-month-old mice showing 
increased Gallyas-stained neurofibrillary tangles and thioflavin-S positive cells in 
APP/PS1/SREBP-2 mice. Scale bar: 50 µm.  
Figure 6.  Activation profiles of different kinases associated with tau phosphorylation. 
(A) Representative immunoblots of cerebral homogenates from WT and indicated 
mutant mice using antibodies against the non-phosphorylated and active phosphorylated 
forms of ERK 1/2, JNK, and p38 MAPK. As shown, all three MAPK pathways were 
activated in APP/PS1/SREBP-2 mice. (B) Western blot analysis of GSK-3β activation 
with antibodies against Y279 and Y216 (activating sites) and Ser9 (inhibitory site) 
indicating enhanced GSK-3β activity in APP/PS1 mice that overexpress SREBP-2. (C) 
Representative immunoblots showing increased levels of phosphorylated CDK5 and 
enhanced cleavage of p35 (CDK5 activator protein) at 10 month of age in brain extracts 
from APP/PS1/SREBP-2 mice. (D) Western blot analysis of PP2A activation using the 
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PP2A C subunit antibody and the phospho-specific antibody that recognize the 
inhibitory phosphorylation at Tyr307 in subunit C.  
Figure 7.  Increased proteolytic cleavage of tau protein in mice harboring the SREBP-2 
transgene. (A) Representative immunoblot of total tau showing cleaved tau presence in 
brain extracts from SREBP-2 and APP/PS1/SREBP-2 mice at the indicated ages. (B) 
Western blot analysis of calpain activity by means of increase in the 145/150-kDa 
specific spectrin cleaved products. Quantification of the 145/150:240 kDa spectrin ratio 
exhibited a significant calpain activity increase in brain extracts from 7-month-old 
mutant mice compared to WT mice. (C) Representative protein immunoblot of 
cathepsin D (33 kDa and 48 kDa, mature and immature forms, respectively) from brain 
extracts of 7-month-old WT and indicated mutant mice. Quantification of the 33:48-
kDa ratio indicates an increased processing of cathepsin D in cerebral extracts from 
SREBP-2 and APP/PS1/SREBP-2 mice. (D) Cathepsin D activity analyzed in brain 
extracts from WT and transgenic mice (A.U.: arbitrary units). *P< 0.05 vs. WT values 
(n = 3). Values are mean ± S.D. 
Figure 8.  In vivo GSH ethyl ester treatment recovers mGSH and prevents tau 
pathology and Aβ deposition in APP/PS1/SREBP-2 mice. 7-month-old WT and 
APP/PS1/SREBP-2 mice were treated with GSH ethyl ester (GSHee; i.p. 1.25 
mmol/kg/day) for 2 week. (A-B) Mitochondrial GSH levels and protein carbonyl 
content after GSHee therapy. * P< 0.01, ** P< 0.05 (n = 6). Values are mean ± S.D. (C) 
Representative immunoblots (non-phosphorylated and active phosphorylated forms) of 
JNK/SAPK, ERK 1/2, and p38 MAP kinases showing reduced activation in brain 
extracts of APP/PS1/SREBP-2 mice after GSHee treatment. (D) Western blot analysis 
of GSK-3β activation with antibodies against Y279 and Y216 (activating sites) and 
CDK5 phosphorylation showing an enhanced activity of both kinases in 
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APP/PS1/SREBP-2 mice independently of GSHee treatment. (E) Representative 
immunoblots showing reduced tau phosphorylation at Ser 396 in brain extracts of 
APP/PS1/SREBP-2 mice after GSHee treatment. Total tau levels were detected by the 
phosphorylation-independent antibody Tau-5. (F) Protein immunoblots of total tau 
(Tau-5) in crude (s-soluble) and sarcosyl-insoluble (s-insoluble) fractions showing 
decreased presence of insoluble tau in APP/PS1/SREBP-2 mice  after GSHee treatment. 
(G) Western blot analysis of β-CTFs using Aβ antibody (clone 6E10). The levels of β-
CFTs were normalized to β-actin (left graph). (H-I) Representative immunofluorescent 
images of amyloid plaques stained with Aβ antibody (clone 6E10) (H) and thioflavin S 
(I). (J) Quantification of Aβ immunoreactivity and thioflavin staining by integrated 
density analysis showing decreased amyloid burden in hippocampus from 
APP/PS1/SREBP-2 mice after GSHee treatment. (AU: arbitrary units).  *P< 0.001 (n = 
4). Values are mean ± S.D. (K) Representative immunoblot of synaptophysin (synapt.) 
protein levels. 
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A 
 
Homogenate 
 WT SREBP-2 APP/PS1 APP/PS1/SREBP-2 
4-month 113.7 ± 7.2 160.9 ± 20.4 * 103.6 ± 8.2 171.4 ± 17.7 * 
7-month 110.4 ± 11.4 144.5 ± 7.70 * 105.4 ± 9.1 166.3 ± 9.10 * 
10-month 113.6 ± 2.7 140.9 ± 13.6 * 170.9 ± 29.9* 154.5 ± 23.6 * 
 
Mitochondria 
 WT SREBP-2 APP/PS1 APP/PS1/SREBP-2 
4-month 5.67 ± 0.46 10.89 ± 1.82 * 5.22 ± 1.13 12.48 ± 3.18 * 
7-month 5.01 ± 1.67 10.82 ± 2.91 * 4.08 ± 1.13 11.98 ± 1.87 * 
10-month 4.86 ± 2.04 13.80 ± 0.59 * 15.29 ± 4.46 * 17.52 ± 2.01 * 
 
B 
 
Mitochondria 
 WT SREBP-2 APP/PS1 APP/PS1/SREBP-2 
4-month 3.58 ± 0.68 1.95 ± 0.16 * 3.67 ± 0.74 1.61 ± 0.19 * 
7-month 3.31 ± 0.30 1.93 ± 0.23 * 2.95 ± 0.32 1.70 ± 0.36 * 
10-month 3.44 ± 0.56 1.82 ± 0.38 * 1.77 ± 0.44 * 1.52 ± 0.58 * 
 
 
Table 1.  Increased cholesterol levels associated with mitochondrial GSH depletion in 
mice carrying the SREBP-2 transgene. (A) Total cholesterol from brain homogenate 
and isolated mitochondria. (B) Mitochondrial GSH. *p<0.05 vs. WT values. (n = 8 per 
genotype). Values are mean ± S.D.; mean differences were compared by one-way 
ANOVA with Dunnett’s post hoc test.  
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Antibody Source and type Company WB dilution 
IHC/IF 
dilution 
8-hydroxyguanosine Goat polyclonal Calbiochem  1:200 
Aβ human (6E10) Mouse monoclonal Sigma-Aldrich 1:1000 1:300 
Cathepsin D Goat polyclonal Santa Cruz Biotech 1:500  
CDK5 Rabbit polyclonal Santa Cruz Biotech 1:500  
ERK1/2 Rabbit polyclonal Cell Signaling 1:1000  
F4/80 Rat monoclonal Santa Cruz Biotech  1:200 
GAPDH (6C5) Mouse monoclonal Santa Cruz Biotech 1:5000  
GFAP Rabbit polyclonal Dako  1:500 
GSK3β Rabbit monoclonal Cell Signaling 1:1000  
MAP2 Rabbit polyclonal Chemicon (Millipore)  1:500 
MBP Rat monoclonal Chemicon (Millipore)  1:500 
p35 (C-19) Rabbit polyclonal Santa Cruz Biotech 1:200  
p38 MAPK Rabbit polyclonal Cell Signaling 1:1000  
PHF-Tau (AT8) Mouse monoclonal BioScience 1:1000 1:200 
Phospho-CDK5 (Tyr15) Rabbit polyclonal Santa Cruz Biotech 1:500  
Phospho-ERK1/2 (Thr202/Tyr204) Mouse monoclonal Cell Signaling 1:1000  
Phospho-GSK3β (Ser9) Rabbit monoclonal Cell Signaling 1:1000  
Phospho-GSK3 α(Y279)/β(Y216) Rabbit polyclonal Invitrogen 1:1000  
Phospho-p38 MAPK (Thr180/Tyr182) Mouse monoclonal Cell Signaling 1:1000  
Phospho-SAPK/JNK (Thr183/Tyr185) Rabbit monoclonal Cell Signaling 1:1000  
Phospho-Tau (Ser396) Rabbit polyclonal Santa Cruz Biotech 1:200  
PP2A (C subunit) Mouse monoclonal Upstate (Millipore) 1:1000  
PP2A Cα/β Mouse monoclonal Santa Cruz Biotech 1:500  
SAPK/JNK Rabbit polyclonal Cell Signaling 1:1000  
Spectrin (AA6) Mouse monoclonal Chemicon (Millipore) 1:1000  
Synaptophysine Rabbit polyclonal Abcam 1:1000  
Tau (TAU-5) Mouse monoclonal Invitrogen 1:1000  
β-actin Mouse monoclonal Sigma-Aldrich 1:10,000  
 
Table 2. Details of the primary antibodies used in this study. 
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ABBREVIATIONS 
 
AD: Alzheimer’s disease 
APP: amyloid precursor protein 
Aβ: amyloid-β 
CDK5: cyclin-dependent kinase 5  
ERK 1/2: extracellular signal-regulated kinase 1/2  
GAPDH: glyceraldehyde-3-phosphate dehydrogenase 
GFAP: glial fibrillary acidic protein  
GGPP: geranylgeranylpyrophosphate 
GSHee: glutathione ethyl ester  
GSK-3β: glycogen synthase kinase-3 beta 
IL-1β: interleukine-1 beta  
MAPK: mitogen-activated protein kinase  
MAP2: microtubule-associated protein 2  
MBP: myelin basic protein  
mGSH: mitochondrial glutathione  
MWM: Morris water maze 
NFT: neurofibrillary tangle 
NPC: Niemann-Pick type C disease 
PP2A: phosphatase 2A  
PS: presenilin 
SAPK/JNK: stress-activated protein kinase/Jun-amino-terminal kinase  
SREBP-2: sterol regulatory element-binding protein-2 
WT: wild-type 
8-OHG: 8-hydroxyguanosine 
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SUPLEMMENTAL FIGURES 
 
 
 
Figure S1. Quantitative analysis of mouse Aβ levels. Brain from WT and indicated 
mutant mice (S-2, Tg-SREBP-2 mice; A/P, APP/PS1 mice; A/P/S-2, APP/PS1/SREBP-
2 mice) were homogenized with guanidine HCl extraction buffer, and the homogenates 
were analyzed by ELISAs for quantitative assessment of mouse Aβ(1-42) content at the 
indicated ages (n = 6-11 per genotype). 
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Figure S2. Protein carbonyl content from brain of the indicated genotype (WT: wild-
type mice, S-2: SREBP-2 mice; A/P: APP/PS1 mice; A/P/S-2: APP/PS1/SREBP-2 
mice) analyzed by inmunoblotting. 
 
 
Figure S3. Activation of astrocytes analyzed by GFAP immunostaining. Representative 
immunohistochemical photomicrographs of hippocampus from 10-month-old mice 
showing increased GFAP staining in APP/PS1/SREBP-2 mice. Scale bar: 100 µm. 
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Figure S4. Confocal analysis of phosphorylated tau (AT8) in hippocampus from 10-
month-old APP/PS1/SREBP-2 mice. Representative images of 
immunofluorescence staining for AT8 (in red) and MAP2 (neurons), GFAP (astrocytes) 
or MBP (oligodendrocytes) (in green) showing colocalization of tau exclusively with 
the neuronal marker MAP2. Scale bar: 10 µm. 
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Figure S5. Activation profiles of different kinases associated with tau phosphorylation. 
The ratio of the immunoreactivity of the phosphorylated form and the total level of each 
kinase was calculated as indicator of activity. (A) Ratio of ERK 1/2, JNK, and p38 
MAP kinases activation. (B) Ratio of GSK-3β activation analyzed with antibodies 
against Y279 and Y216 (activating sites) and Ser9 (inhibitory site). (C) Ratio of CDK5 
activation and p25 levels (n = 3). *P< 0.05 vs. WT values. Values are mean ± S.D.  
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Figure S6. Analysis of intracellular β-sheet-rich structures by thioflavin S staining. 
Representative photomicrographs of hippocampal CA1 regions from 7-month-old 
APP/PS1/SREBP-2 mice showing reduced intracellular thioflavin S staining after GSH 
ethyl ester (GSHee) treatment. Scale bar: 10 µm. 
